What is the specific mechanism of action of Trabectedin?

Trabectedin is unique in that it is not a cytotoxic drug in the traditional sense, but interferes with the growth and survival of tumor cells through complex and multiple mechanisms. Its core mechanism of action is to bind to the secondary groove of DNA and change the helical structure of DNA. This combination will hinder the normal work of transcription factors and DNA repair proteins, leading to obstacles in the replication and repair processes of tumor cells, thereby inducing apoptosis.

Unlike the single killing mode of many classic chemotherapy drugs, trabectedin can also affect the tumor microenvironment. Studies have found that it can inhibit the function of tumor-associated macrophages and reduce the release of pro-inflammatory factors and growth factors in the tumor microenvironment, thus weakening the support system that tumor cells rely on to survive and spread. This"double hit" mode allows trabectedin to not only directly act on cancer cells, but also indirectly inhibit cancer progression by regulating the immune microenvironment.

In addition, trabectedin'sDNA binding is selective and it is more likely to act on certain specific DNA sequences. This selectivity makes it more sensitive to some tumor subtypes. Because the molecular characteristics of different tumors vary, the efficacy of trabectedin will also vary depending on the patient's genetic background and tumor characteristics. Therefore, researchers are exploring biomarkers that predict sensitivity to help select those most suitable for treatment with trabectedin.

The data also pointed out that trabectedin may have a synergistic effect when combined with other chemotherapy drugs or targeted drugs. For example, it can enhance anti-tumor responses when combined with platinum-based drugs or immune checkpoint inhibitors. This mechanism study provides a theoretical basis for clinical expansion of combination therapy, and also demonstrates the important potential of trabectedin in the context of precision medicine.

Reference materials:https://www.drugs.com/monograph/trabectedin.html